Benitec Biopharma Inc
NASDAQ:BNTC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Destination XL Group Inc
NASDAQ:DXLG
|
US |
Benitec Biopharma Inc
Total Current Liabilities
Benitec Biopharma Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Benitec Biopharma Inc
NASDAQ:BNTC
|
Total Current Liabilities
$2m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$43.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$11.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$25.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Total Current Liabilities
$641.2m
|
CAGR 3-Years
16%
|
CAGR 5-Years
0%
|
CAGR 10-Years
37%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
Benitec Biopharma Inc
Glance View
Benitec Biopharma, Inc. is a development-stage biotechnology company, which focuses on the advancement of novel genetic medicines. The company is headquartered in Hayward, California and currently employs 14 full-time employees. The company went IPO on 2012-07-11. The firm is focused on developing a therapeutic technology platform that combines ribonucleic acid (RNA) interference with gene therapy for the goal of silencing disease-causing genes from a single administration. The firm's technology, deoxyribonucleic acid (DNA)-directed RNA interference (ddRNAi), is used to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Its pipeline includes BB-301, and BB-103. The firm's lead product candidate, BB-301, is used for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). Its BB-103 pipeline product is being developed for the treatment of chronic hepatitis B Virus infection.
See Also
What is Benitec Biopharma Inc's Total Current Liabilities?
Total Current Liabilities
2m
USD
Based on the financial report for Dec 31, 2025, Benitec Biopharma Inc's Total Current Liabilities amounts to 2m USD.
What is Benitec Biopharma Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
21%
Over the last year, the Total Current Liabilities growth was -34%. The average annual Total Current Liabilities growth rates for Benitec Biopharma Inc have been -7% over the past three years , 21% over the past five years .
